Search results
Gilead Sciences (GILD) Q2 2022 Earnings Call Transcript
Motley Fool· 2 years agoThe speakers on today's call will be our chairman and chief executive officer, Daniel O'Day; our...
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Investor's Business Daily· 1 year agoGilead Sciences' first-in-class cancer drug and GILD stock are finally hitting their stride. The...
Gilead Breaks Out In Bullish Volume As Its Cancer Drug Sales Nearly Double
Investor's Business Daily· 1 year agoGilead Sciences crushed third-quarter expectations as sales of its cancer drugs nearly doubled,...
Gilead reports lower 3rd-quarter profit as COVID drug sales slow
Reuters via Yahoo Finance· 1 year agoGilead Sciences Inc on Thursday said third-quarter profit fell due to lower sales of its COVID-19...
Why Gilead Sciences Stock Is Falling Today
Benzinga via Yahoo Finance· 12 months agoGilead Sciences Inc (NASDAQ: GILD) reported Q1 FY23 sales decreased 4% Y/Y to $6.35 billion, slightly above the consensus of $6.33 billion, due to lower...
Twice-Yearly HIV Treatment Approved for Those With Drug Resistance
Plus via Yahoo News· 1 year agoThe U.S. Food and Drug Administration approved the drug Sunlenca (lenacapavir), produced by Gilead...
Gilead reviewing drug acquired in $5B buyout after latest setback
BioPharma Dive via Yahoo Finance· 2 months agoGilead Sciences is evaluating the future of a cancer drug acquired in a multibillion-dollar deal...
Sheryl Lee Ralph is Helping Tell Real Stories of Black Women Living With HIV
Plus via Yahoo News· 1 year agoWith her exuberant energy and ageless beauty, it’s hard to believe that the career of legendary...
